Mostrar el registro sencillo

dc.contributor.authorRodríguez-Rodríguez, Luises_ES
dc.contributor.authorLópez Mejías, Raqueles_ES
dc.contributor.authorGonzález Juanatey, Carloses_ES
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel es_ES
dc.contributor.authorMartín, Javieres_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-01-31T13:44:04Z
dc.date.available2024-01-31T13:44:04Z
dc.date.issued2012es_ES
dc.identifier.issn0962-9351es_ES
dc.identifier.issn1466-1861es_ES
dc.identifier.urihttps://hdl.handle.net/10902/31357
dc.description.abstractCardiovascular (CV) disease is the most common cause of premature mortality in patients with rheumatoid arthritis (RA). It is the result of an accelerated atherosclerotic process. Both RA and atherosclerosis are complex polygenic diseases. Besides traditional CV risk factors and chronic inflammation, a number of studies have confirmed the role of genetic factors in the development of the atherogenesis observed in RA. In this regard, besides a strong association between the HLA-DRB1*04 shared epitope alleles and both endothelial dysfunction, an early step in the atherosclerotic process, and clinically evident CV disease, other polymorphisms belonging to genes implicated in inflammatory and metabolic pathways, located inside and outside the HLA region, such as the 308 variant (G>A, rs1800629) of the TNFA locus, the rs1801131 polymorphism (A>C; position + 1298) of the MTHFR locus, or a deletion of 32 base pairs on the CCR5 gene, seem to be associated with the risk of CV disease in patients with RA. Despite considerable effort to decipher the genetic basis of CV disease in RA, further studies are required to better establish the genetic influence in the increased risk of CV events observed in patients with RA.es_ES
dc.description.sponsorshipThis study was supported by 2 Grants from the Fondo de Investigaciones Sanitarias, PI06-0024 and PI09/007/48 (Spain). This work was partially supported by the RETICS Program, RD08/0075 (RIER), from Instituto de Salud Carlos III. M. García-Bermúdez is the beneficiary of a grant from the Fundación Española de Reumatología (FER).
dc.format.extent14 p.es_ES
dc.language.isoenges_ES
dc.publisherHindawi Publishing Corporationes_ES
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceMediators of Inflammation, 2012, 574817es_ES
dc.titleGenetic markers of cardiovascular disease in rheumatoid arthritises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1155/2012/574817es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1155/2012/574817es_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International